{"resourceType": "Evidence", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"], "versionId": "9", "lastUpdated": "2025-03-20T18:40:09.616Z"}, "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "urn:ietf:rfc:3986", "value": "https://fevir.net/FOI/293986", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "outcomeId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "313962"}, {"type": {"text": "picoId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "85798"}, {"type": {"text": "sectionId"}, "system": "https://app.magicapp.org/#/guidelines", "value": "73215"}], "name": "Diabetic_ketoacidosis_Intervention_Evidence_from_MAGICapp_313962", "title": "MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes", "status": "active", "author": [{"name": "Computable Publishing\u00ae: MAGIC-to-FEvIR Converter"}], "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "InterventionOnlyEvidence", "display": "InterventionOnlyEvidence"}]}}], "variableDefinition": [{"description": "Adults with type 2 diabetes -- SGLT2 inhibitors", "variableRole": "population", "observed": {"type": "Group", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-intervention-group-MAGIC-5288-j1Wqrn-intervention-85394-I-85798", "assigner": {"display": "Computable Publishing LLC"}}, "display": "SGLT2 inhibitors Group in Adults with type 2 diabetes", "reference": "Group/236949"}}, {"description": "Diabetic ketoacidosis", "variableRole": "outcome", "observed": {"type": "EvidenceVariable", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-313962", "assigner": {"display": "Computable Publishing LLC"}}, "display": "Diabetic ketoacidosis", "reference": "EvidenceVariable/236971"}}], "statistic": [{"description": "Risk 0.2%", "statisticType": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/statistic-type", "version": "5.0.0-cibuild", "code": "C44256", "display": "Proportion"}]}, "quantity": {"value": 0.002}}], "url": "https://fevir.net/resources/Evidence/293986", "id": "293986", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "extension": [{"extension": [{"url": "type", "valueCode": "part-of"}, {"url": "targetReference", "valueReference": {"type": "Composition", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-conversion-report", "assigner": {"display": "Computable Publishing LLC"}}, "display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"}}], "url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/relates-to"}], "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."}